Deodhar, Suyash http://orcid.org/0000-0003-1536-6761
Sillman, Brady http://orcid.org/0000-0002-7123-3034
Bade, Aditya N.
Avedissian, Sean N. http://orcid.org/0000-0002-0935-6455
Podany, Anthony T.
McMillan, JoEllyn M.
Gautam, Nagsen
Hanson, Brandon
Dyavar Shetty, Bhagya L.
Szlachetka, Adam
Johnston, Morgan
Thurman, Michellie
Munt, Daniel J.
Dash, Alekha K.
Markovic, Milica http://orcid.org/0000-0002-3998-1833
Dahan, Arik http://orcid.org/0000-0002-3498-3514
Alnouti, Yazen
Yazdi, Alborz
Kevadiya, Bhavesh D.
Byrareddy, Siddappa N. http://orcid.org/0000-0002-6889-4640
Cohen, Samuel M. http://orcid.org/0000-0002-5047-0962
Edagwa, Benson http://orcid.org/0000-0003-1484-9331
Gendelman, Howard E. http://orcid.org/0000-0002-7831-0370
Article History
Received: 12 January 2022
Accepted: 20 May 2022
First Online: 9 June 2022
Competing interests
: B.E. and H.E.G. are named inventors on patents (US011166957B2, WO2021035114A1, EP3886863A1, WO2019199756A1, US20200390796A1) that cover the medicinal and polymer chemistry technologies employed in this manuscript, encompassing the synthesis of long-acting dolutegravir prodrug and formulation manufacturing. A.Y., B.E., and H.E.G. are co-founders of Exavir Therapeutics, Inc., a biotechnology company that is developing extended-release long-acting antiretroviral drugs. H.E.G. is the Interim Director and B.S. is the Operations Manager of the Nebraska Nanomedicine Production Plant, a good manufacturing program facility. The authors declare that this work was produced solely by the authors and that no other individuals or entities influenced any aspects of the work including, but not limited to, the study conception and design, data acquisition, analyses and interpretation, and writing of the manuscript. No other entities provided funds for the work. The authors further declare that they have received no financial compensation from any other third parties for any aspects of the published work. The remaining authors declare no competing interests.